Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P F Ferrucci, P A Ascierto, J Pigozzo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2013
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
Michele Del Vecchio, Lorenza Di Guardo, Paolo A Ascierto, et al.
Melanoma Research
|
January 3, 2020
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Victoria Atkinson, Shahneen Sandhu, Geke Hospers, et al.
Nature Biomedical Engineering
|
February 12, 2025
A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma
Mattia Ballerini, Serena Galiè, Punit Tyagi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 7, 2023
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile
Paolo A Ascierto, Anna M Di Giacomo, Vanna Chiarion Sileni, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Cell Host & Microbe
|
October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients
Angeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine
|
June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P F Ferrucci, P A Ascierto, J Pigozzo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2013
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
Michele Del Vecchio, Lorenza Di Guardo, Paolo A Ascierto, et al.
Melanoma Research
|
January 3, 2020
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
Victoria Atkinson, Shahneen Sandhu, Geke Hospers, et al.
Nature Biomedical Engineering
|
February 12, 2025
A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma
Mattia Ballerini, Serena Galiè, Punit Tyagi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 7, 2023
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile
Paolo A Ascierto, Anna M Di Giacomo, Vanna Chiarion Sileni, et al.
The New England Journal of Medicine
|
September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Cell Host & Microbe
|
October 31, 2024
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients
Angeli D G Macandog, Carlotta Catozzi, Mariaelena Capone, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine
|
June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Page
of 5